CJC-1295 with DAC

Research Specification: CJC-1295 with DAC Peptide

CJC-1295 with DAC (Drug Affinity Complex) constitutes an engineered peptide analog formulated based on the natural secretagogue known as growth hormone–releasing hormone (GHRH). The engineering approach centered on addressing inherent instability through strategic molecular modifications that enhance persistence and extend the therapeutic window. The DAC moiety facilitates interaction with albumin proteins abundant in serum, thereby mitigating clearance mechanisms involving kidney filtration and enzymatic hydrolysis. This translates to amplified and sustained stimulation of GH secretion substantially exceeding the response magnitude and duration achievable with native GHRH molecules.

Operational Framework and Biological Significance

CJC-1295 incorporating the Drug Affinity Complex represents an engineered analog of GHRH exhibiting extended pharmacokinetic properties and heightened capacity for GH stimulation. Administration allows the peptide to activate GHRH receptors present on anterior pituitary somatotrophs, triggering intracellular signaling mechanisms that evoke pulsatile GH discharge consistent with normal endogenous patterns.

Once secreted into bloodstream, GH triggers synthesis and secretion of insulin-like growth factor-1 (IGF-1) by the liver and other organ systems, establishing IGF-1 as the critical effector responsible for promoting anabolic metabolism, accelerating tissue restoration, and facilitating cellular replication. The interplay between GH and IGF-1 establishes a primary control system for metabolic equilibrium, mobilization of energy substrates from adipose tissues, and accumulation of contractile proteins in skeletal muscle. In particular, GH acts to increase lipid breakdown across visceral and subcutaneous adipose compartments while maintaining skeletal muscle mass and function.

The DAC modification imparts a critical advantage by enabling stable association with the dominant serum protein, albumin. This albumin-peptide complex dramatically extends residence time in the circulatory system, perpetuating continuous activation of target receptors and uninterrupted GH secretion signaling. As a result, CJC-1295 with DAC demonstrates biological activity persisting over days to weeks—markedly exceeding the brief functional window characteristic of non-DAC analogs including standard CJC-1295 or unaltered GHRH(1-29).

From a biochemical standpoint, CJC-1295 engagement with GHRH receptors presumably initiates cAMP-dependent signaling cascades mediated by adenylate cyclase activation. Subsequent mobilization of protein kinase A (PKA) occurs, catalyzing phosphorylation events in key regulatory transcription factors and promoting increased expression of GH-related genes within pituitary somatotroph populations. Prolonged persistence of the albumin-bound peptide sustains these signal transduction events, producing cumulative enhancements in GH output and corresponding increases in IGF-1 when compared to shorter-acting peptide compounds.

Overall, CJC-1295 with DAC provides an excellent research platform for examining extended hormonal stimulation phenomena, delineating the regulatory architecture of the GH/IGF-1 network, and quantifying metabolic and physiological consequences arising from prolonged GH secretion pulsatility.

Molecular and Chemical Composition

Chemical Properties and Characterization

Appearance: White powder in lyophilized state

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: Approximately 3647.9 g/mol

Sequence Identity: GHRH(1–29) framework containing integrated DAC component

Purity Assurance: ≥ 98% as verified through Certificate of Analysis

CJC-1295 with DAC: Research Protocols and Quality Standards

Storage Conditions and Chemical Stability

CJC-1295 with DAC is supplied as a sterile, lyophilized peptide formulation engineered for research applications. Preservation of the compound's molecular structure and biological capacity requires maintenance at –20°C in the powder form. Following reconstitution in appropriate vehicle, the solution should be processed using sterile technique and stored at 2–8°C for immediate experimental use. These storage requirements protect against chemical degradation and minimize the possibility of microbial contamination during laboratory procedures.

Growth Hormone Secretory Response

Research in both clinical human subjects and preclinical animal systems indicates that a single administration of CJC-1295 with DAC generates elevated circulating levels of GH and IGF-1 persisting approximately one week. This prolonged endocrine elevation contrasts sharply with the momentary response produced by native GHRH(1-29) or non-DAC peptide formulations. Measured values demonstrate IGF-1 concentrations approximately 2–3 times higher than baseline, coordinated with maintained GH pulsatile patterns, confirming robust cellular receptor engagement and prolonged bioavailability of the administered peptide.

Metabolic Alterations Associated with CJC-1295 with DAC

Scientific evidence indicates CJC-1295 with DAC produces substantial alterations in metabolic state through mechanisms involving increased GH and IGF-1 availability. Preclinical research observations document heightened adipose tissue lipolysis, augmented fat oxidative catabolism, and preserved lean body mass composition, all consistent with recognized GH metabolic activities. Investigation has examined peptide effects on amino acid incorporation into structural proteins, tissue repair acceleration, and energy utilization rates, providing valuable research capability for investigating GH-dependent metabolic systems.

Circulation Half-Life and Extended Bioavailability

Differentiated from rapid-acting GHRH compounds, the DAC element of CJC-1295 enables stable albumin binding, substantially reducing both kidney-mediated elimination and enzymatic inactivation. The robust interaction between the peptide and serum albumin remarkably extends the compound's active lifespan in circulation, facilitating continuous receptor signaling and perpetual endocrine stimulation. Pharmacokinetic calculations show the compound maintains a terminal half-life of approximately 5.8 to 8.1 days—substantially exceeding the minutes-to-hours clearance pattern of non-albumin-conjugated alternatives—thereby enabling reduced dosing schedules in experimental settings.

Literature Assembly and Scholarly Attribution

Manuscript Composition and Editorial Functions

This comprehensive scientific literature review was carefully compiled, critically evaluated, and systematically arranged by Dr. Stuart L. Teichman, M.D. A distinguished endocrinologist and clinical researcher, Dr. Teichman has conducted pioneering investigations into protracted-action GHRH analogs, particularly focusing on CJC-1295. His groundbreaking studies have elucidated the pharmacological characteristics, safety considerations, and therapeutic promise of GHRH-based peptide compounds, demonstrating their capacity to sustain elevated GH and IGF-1 in circulation. Dr. Teichman's scientific achievements have profoundly impacted the discipline of peptide endocrinology and the development of extended-duration hormonal therapeutics.

Scholarly Collaborations and Research Output

Throughout his academic and clinical career, Dr. Stuart L. Teichman has concentrated his research efforts on growth hormone secretion inducers, GHRH-derived peptide compounds, and peptide-mediated endocrine regulation. In collaboration with respected researchers A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has generated substantial scientific publications examining the molecular mechanisms of extended-action GHRH preparations, their regulatory influence on the GH/IGF-1 system, and their comprehensive physiological metabolic effects. His collective scientific body of work establishes a foundational knowledge base for development of next-generation peptide-based therapeutic agents directed toward metabolic wellness and hormonal balance.

This attribution is presented solely for recognition of scientific contributions and must not be construed as a professional endorsement, promotional statement, or declaration of organizational affiliation. Montreal Peptides Canada maintains no partnership, sponsorship agreement, or professional relationship with Dr. Teichman or any referenced colleagues.

Literature Citations and Resources

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/

Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/